Scanfil raises growth target to 15% a year
Scanfil is raising its long-term turnover growth target from 10% to 15% on average per year over the business cycle. At the same time, the EMS provider is giving itself more financial room for further acquisitions.
The net debt to EBITDA target is now set at 1–2, compared with a previous ceiling of 1.5, according to a press release from Scanfil. The company's other long-term targets are a comparable EBITA margin of 7–8% and a dividend of approximately one third of earnings per share.
The company attributes the raised targets to both organic growth and the acquisitions completed in the USA, Italy and the Asia-Pacific region over the past two years, which have been carried out while maintaining a healthy balance sheet and stable profitability.
"Our ambition is to be an active consolidator in the high-mix, low to mid volume EMS market and create value through both organic growth and acquisitions," says CEO Christophe Sut.
The global EMS market is expected to grow by 5.6% annually until 2030. Scanfil expects to outpace that organically, driven by its four key customer segments: Aerospace & Defense, Energy & Cleantech, Industrial, and Medtech & Life Science. The company points to customers increasingly outsourcing manufacturing to gain flexibility, reduce capital intensity and build more resilient supply chains, while rising defense spending, the energy transition and an ageing population support demand in the respective segments.
Guidance for 2026 remains unchanged, with turnover expected at EUR 940–1,060 million and comparable EBITA at EUR 64–78 million.
